A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer

European Journal of Cancer

Volumn 48, Issue 6, 2012, Pages 820-826

  Ferrarotto, Renata ^a   MacHado, Karime ^b   Mak, Milena P ^b   Shah, Neeraj ^c   Takahashi, Tiago K ^b   Costa, Frederico P ^a   Overman, Michael J ^c   Kopetz, Scott ^c   Hoff, Paulo M ^a,b  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Metastatic colorectal cancer; Mitomycin C; Refractory setting

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ADULT; AGED; COLORECTAL CANCER; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HEMOLYTIC UREMIC SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84862815695     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.01.008     Document Type: Article

References (25)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2 2005 74 108 (Pubitemid 40372904)
2. P. Rougier, E. Van Cutsem, and E. Bajetta Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Lancet 352 9138 1998 1407 1412 (Pubitemid 28510873)
3. C.S. Fuchs, J. Marshall, and E. Mitchell Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study J Clin Oncol 25 30 2007 4779 4786 (Pubitemid 350086481)
4. C. Tournigand, T. Andre, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2 2004 229 237 (Pubitemid 41095086)
5. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342 (Pubitemid 38702844)
6. E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 14 2009 1408 1417
7. M. Peeters, T.J. Price, and A. Cervantes Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 31 2010 4706 4713
8. C.G. Moertel, R.J. Reitemeier, and R.G. Hahn Mitomycin C therapy in advanced gastrointestinal cancer JAMA 204 12 1968 1045 1048 [Epub 1968/06/17]
9. L. Rimassa, G. Gullo, and C. Carnaghi Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin Tumori 92 4 2006 285 289 [Epub 2006/10/14] (Pubitemid 44525303)
10. C. Vaklavas, A.M. Tsimberidou, and S. Wen Phase 1 clinical trials in 83 patients with pancreatic cancer: The M.D. Anderson Cancer Center experience Cancer 117 1 2011 77 85 [Epub 2010/08/26]
11. P. Ross, A. Norman, and D. Cunningham A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer Ann Oncol 8 10 1997 995 1001 [Epub 1997/12/24] (Pubitemid 27475731)
12. N. Gyldenkerne, B. Glimelius, and J.E. Frodin A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer Acta Oncol 43 3 2004 276 279 [Epub 2004/07/13] (Pubitemid 38757049)
13. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16(1):301-08 [Epub 1998/01/24].
14. N.C. Tebbutt, K. Wilson, and V.J. Gebski Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study J Clin Oncol 28 19 2010 3191 3198
15. J.D. Chester, J.T. Dent, G. Wilson, E. Ride, and M.T. Seymour Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer Ann Oncol 11 2 2000 235 237 [Epub 2000/04/13] (Pubitemid 30148743)
16. W. Scheithauer, G.V. Kornek, and S. Brugger Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer Cancer Invest 20 1 2002 60 68 [Epub 2002/02/21] (Pubitemid 34151060)
17. Y. Yamada, K. Shirao, and I. Hyodo Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer Cancer Chemother Pharmacol 52 2 2003 125 130 [Epub 2003/06/05] (Pubitemid 37041345)
18. P. Rougier, D. Lepille, and J. Bennouna Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study Ann Oncol 13 10 2002 1558 1567 [Epub 2002/10/16] (Pubitemid 35331453)
19. G. Chong, J.L. Dickson, and D. Cunningham Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan Br J Cancer 93 5 2005 510 514 (Pubitemid 43079992)
20. G. Rosati, A. Rossi, D. Germano, G. Reggiardo, and L. Manzione Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin a phase II study Anticancer Res 23 2003 2981 2985 [Epub 2003/08/21] (Pubitemid 36969848)
21. D.H. Lim, Y.S. Park, and B.B. Park Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study Cancer Chemother Pharmacol 56 1 2005 10 14 [Epub 2005/03/23] (Pubitemid 41201750)
22. T.J. Price, P.J. Ross, and T. Hickish Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma Clin Colorectal Cancer 3 4 2004 235 242 [Epub 2004/03/18] (Pubitemid 38444310)
23. S. Rao, D. Cunningham, and T. Price Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer Br J Cancer 91 5 2004 839 843 (Pubitemid 39273772)
24. D.J. Jonker, C.J. O'Callaghan, and C.S. Karapetis Cetuximab for the treatment of colorectal cancer N Engl J Med 357 20 2007 2040 2048 (Pubitemid 350106711)
25. H.T. Arkenau, A.T. Brunetto, and J. Barriuso Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer Oncology 76 3 2009 151 156